Chongqing Genrix Valuation Multiples

Chongqing Genrix Overview

About Chongqing Genrix

Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.

Founded

2015

HQ

Employees

N/A

Website

genrixbio.com

Sectors

BiopharmaceuticalsBioTech

Financials (FY)

Revenue: $4M

EBITDA: ($102M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Chongqing Genrix Financials

Chongqing Genrix reported last fiscal year revenue of $4M and negative EBITDA of ($102M).

In the same fiscal year, Chongqing Genrix generated $4M in gross profit, ($102M) in EBITDA losses, and had net loss of ($109M).

Chongqing Genrix P&L

In the most recent fiscal year, Chongqing Genrix reported revenue of $4M and EBITDA of ($102M).

Chongqing Genrix expects next 12-month revenue of XXX and NTM EBITDA of XXX

Chongqing Genrix Stock Performance

Chongqing Genrix has current market cap of $2B, and enterprise value of $1B.

Chongqing Genrix's stock price is $4.56.

Chongqing Genrix Valuation Multiples

Chongqing Genrix trades at 337.1x EV/Revenue multiple, and (14.5x) EV/EBITDA.

Chongqing Genrix Financial Valuation Multiples

As of April 19, 2026, Chongqing Genrix has market cap of $2B and EV of $1B.

Equity research analysts estimate Chongqing Genrix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Chongqing Genrix has a P/E ratio of (15.3x).

Chongqing Genrix Margins & Growth Rates

Chongqing Genrix's revenue in the last fiscal year grew by 2384%.

Chongqing Genrix Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Chongqing Genrix M&A Activity

Chongqing Genrix acquired XXX companies to date.

Last acquisition by Chongqing Genrix was on XXXXXXXX, XXXXX. Chongqing Genrix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Chongqing Genrix Investment Activity

Chongqing Genrix invested in XXX companies to date.

Chongqing Genrix made its latest investment on XXXXXXXX, XXXXX. Chongqing Genrix invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).